Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Arix Bioscience acquires 11% stake in Phamaxis Ltd.

London-based Arix Bioscience announced it has acquired an 11 % interest in Pharmaxis in a two tranche placement contributing £8m, while £5.4...

Sobi in €387m orphan drug deal with Novimmune

The exclusive licence agreement will give Sobi the rights to emapalumab, an anti-interferon-gamma monoclonal antibody, which currently being reviewed...

Afatinib push back K-RAS-positive lung cancer

In mice, two Austrian teams led by Herwig Moll  and Björn Kruspig from Medical University Vienna  showed independently that the...

EU’s single-use plastic rules boost bioplastics

Charging for plastic bags, banning plastic straws: In Western Europe, legislators are set to curb the ubiquitousness of single-use plastics. The...

ReViral raises US$55m

ReViral focusses on infections caused by the Respiratory Syncytial Virus (RSV). It is the most important respiratory pathogen, with 30 million...

Chugai ends licence for PharmaMar’s lurbinectedin

As a compensation, PharmaMar received a payment of €3m from Chugai who had announced it will terminate the commercialisation agreement for the...

Roche granted breakthrough status for liver cancer combo

Based on data from a Phase Ib study, Tecentriq (atezolizumab) in combination with Avastin (bevacizumab) were given the breakthrough designation as a...